

HTL accelerates its development strategy with the appointment of François Fournier as Chief Executive Officer from September 1st, 2022

Javené, June 8th, 2022 – HTL Biotechnology (HTL), a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, accelerates its development strategy with the appointment of François Fournier as Chief Executive Officer (CEO).

François will be appointed as CEO of HTL from September 1st, 2022. An experienced healthcare executive and expert in HTL's therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years' experience in corporate strategy, business execution, and international leadership. Prior to joining HTL, François Fournier, of French and American nationality, worked in many countries and several continents in different management positions at pharmaceutical companies, including most recently at Virbac (as president and CEO of Virbac North America based in Dallas) and previously at Smith & Nephew and Galderma.

"I am delighted to join HTL, a market leader in the development and production of innovative pharmaceutical grade biopolymers. HTL is a fast-growing company with a high-quality expert team that has accelerated growth and innovation through R&D. Together with the management team, we will continue to put all our experience at the service of HTL's purpose and its ambitious strategy, which will enable us to consolidate our leadership position internationally and drive our growth." says François Fournier, CEO, HTL.

Former Chief Executive Officer Yvon Bastard will join the board of directors of HTL and will also serve as Global Chief Operating Officer from September, reporting to François Fournier.

The management team will be further strengthened by the arrival of Nicolas Préfol as Group Chief Financial Officer. Nicolas has more than 20 years of experience in several positions in many countries at international industrial companies, previously working at SEPRO and General Electric.

###

About HTL

HTL is the world leader in the development and production of pharmaceutical grade biopolymers used to develop life-changing treatments for millions of patients.

A pioneer in the bioproduction of hyaluronic acid, HTL has developed and refined for over 30 years its innovative functional biopolymer platform that has enabled it to produce "customised" pharmaceutical grade products for the leaders of the pharmaceutical and medical devices sectors in therapeutic areas such as ophthalmology, dermatology, medical aesthetics, rheumatology and urology

Thanks to its dedicated R&D team, its partnerships and its incubator, HTL is now driving innovation in the biopolymer sector. Its R&D strategy aims to address unmet medical needs by creating new types of biopolymers, modifying their physico-chemical properties, and exploring new medical applications in cutting-edge areas such as bioprinting and drug delivery.

For more information on HTL: <https://htlbiotech.com/>

Contact presse

Nathalie Chevallon – HTL

nchevallon@htlbiotech.com / +33 7 61 45 26 85

Camille Briquet – APCO Worldwide

htl@apcoworldwide.com / +33 7 76 15 73 85